Phase II Study Of Niraparib In Patients With PALB2 Mutated Locally Advanced Or Metastatic Solid Tumors, Including Pancreatic Cancer
The purpose of this phase II study is to evaluate the safety and efficacy of niraparib in patients with locally advanced or metastatic PALB2 (tPALB2) mutation solid tumors, including pancreatic cancer.
Study ID: TMPS-101
Trial Phase: Phase II
Trial Sponsor: Tempus Labs
Therapies Used in This Trial: Niraparib